Medtech CDMOs in Southeast Asia: Landscape Overview and Investment Opportunities (L.E.K. Consulting)

Summary

• MedTech original equipment manufacturers (OEMs) feature long product life cycles ranging from 8 to 15 years, requiring complex onboarding and regulatory validation.p.3
• Valuations in healthcare CDMOs remain elevated, evidenced by Novo acquiring Catalent at an EBITDA multiple of 22.9x in December 2024 compared to approximately 16x for industrial CDMOs.p.3
• Healthcare spending in Southeast Asia is projected to grow at a CAGR of 9% from 2025 to 2029, driving demand for locally manufactured medical devices.p.5
• Private equity investors can capitalize on Southeast Asia CDMO opportunities through geographic expansion to the U.S. and European Union, vertical integration, and targeted M&A.p.6

Key insights

1. CDMOs offer specialized manufacturing and material capabilities that help OEMs reduce capital expenditure and speed up product launch timelines.p.1
2. MedTech CDMOs operate in highly regulated environments requiring compliance with FDA, ISO standards, or CE mark specifications.p.2
3. Long product life cycles of 8 to 15 years create sticky customer relationships, making switching CDMOs rare and costly for OEMs.p.3
4. MedTech devices command higher pricing power than pharmaceuticals or electronics because performance and quality outweigh cost in critical care settings.p.3
5. Global medtech OEMs such as Boston Scientific and Medtronic are expanding manufacturing operations into Southeast Asia.p.4
6. Localization mandates like India's Production Linked Incentive Scheme and Indonesia's TKDN policy compel OEMs to build regional sourcing infrastructure.p.5
7. Southeast Asia provides a geopolitically neutral and stable base for medtech OEMs looking to de-risk supply chains amidst U.S.-China tensions.p.5
8. Special economic zones such as Iskandar SEZ, Saigon Hi-Tech Park, and Batam Free Trade Zone provide tax incentives and infrastructure to attract investment.p.5
9. Private equity firms can exit CDMO platform investments via strategic sales to global manufacturers, initial public offerings, or secondary PE sales.p.6